These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 5002403

  • 1. Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
    Neil GL, Buskirk HH, Moxley TE, Manak RC, Kuentzel SL, Bhuyan BK.
    Biochem Pharmacol; 1971 Dec; 20(12):3295-308. PubMed ID: 5002403
    [No Abstract] [Full Text] [Related]

  • 2. Some determinants of camptothecin responsiveness in leukemia L1210 cells.
    Kessel D.
    Cancer Res; 1971 Dec; 31(12):1883-7. PubMed ID: 5120286
    [No Abstract] [Full Text] [Related]

  • 3. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH, Frei E.
    Clin Pharmacol Ther; 1971 Dec; 12(6):944-54. PubMed ID: 5289712
    [No Abstract] [Full Text] [Related]

  • 4. Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure.
    Grant S, Lehman C, Cadman E.
    Cancer Res; 1980 May; 40(5):1525-31. PubMed ID: 7370990
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075).
    Allen LM, Creaven PJ.
    Cancer Res; 1973 Dec; 33(12):3112-6. PubMed ID: 4796799
    [No Abstract] [Full Text] [Related]

  • 6. Biological and biochemical differences between tubercidin (7-deazaadenosine) and its 5'-phosphate methyl ester.
    Bhuyan BK, Neil GL, Smith CG, Olin EJ, Li LH.
    Cancer Res; 1971 Dec; 31(12):1923-9. PubMed ID: 5120290
    [No Abstract] [Full Text] [Related]

  • 7. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL, Wiley PF, Manak RC, Moxley TE.
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract] [Full Text] [Related]

  • 8. Studies on the mode of action of 2,2'-anhydro-1- -D-arabinofuranosylcytosine.
    Wang MC, Sharma RA, Bloch A.
    Cancer Res; 1973 Jun; 33(6):1265-71. PubMed ID: 4578070
    [No Abstract] [Full Text] [Related]

  • 9. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells.
    Wang JJ, Chervinsky DS, Rosen JM.
    Cancer Res; 1972 Mar; 32(3):511-5. PubMed ID: 5061305
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole.
    Brockman RW, Shaddix S, Laster WR, Schabel FM.
    Cancer Res; 1970 Sep; 30(9):2358-68. PubMed ID: 5475481
    [No Abstract] [Full Text] [Related]

  • 11. Biochemical effects of ellipticine on leukemia L1210 cells.
    Li LH, Cowie CH.
    Biochim Biophys Acta; 1974 Jul 11; 353(3):375-84. PubMed ID: 4368454
    [No Abstract] [Full Text] [Related]

  • 12. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL, Moxley TE, Manak RC.
    Cancer Res; 1970 Aug 11; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract] [Full Text] [Related]

  • 13. Antileukemic activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-beta-D-arabinofuranosylcytosine.
    Khwaja TA, Kigwana LJ, Mian AM.
    Cancer Res; 1979 Aug 11; 39(8):3129-33. PubMed ID: 455296
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor activity and mode of action of 2-thio-6-azauridine (NSC-146268) on L1210 leukemia.
    Li LH, Neil GL, Moxley TE, Olin EJ.
    Cancer Chemother Rep; 1974 Aug 11; 58(3):345-52. PubMed ID: 4858297
    [No Abstract] [Full Text] [Related]

  • 15. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC, Goldberg D, Schein PS.
    Biochem Pharmacol; 1973 Jan 15; 22(2):277-80. PubMed ID: 4763256
    [No Abstract] [Full Text] [Related]

  • 16. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE, Schabel FM, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW.
    Cancer Chemother Rep; 1970 Dec 15; 54(6):431-50. PubMed ID: 5527023
    [No Abstract] [Full Text] [Related]

  • 17. Biochemical studies of a new antitumor agent, O2,2'-cyclocytidine.
    Ho DH.
    Biochem Pharmacol; 1974 Apr 15; 23(8):1235-44. PubMed ID: 4824772
    [No Abstract] [Full Text] [Related]

  • 18. Mechanism of action of tetra-mu-carboxylatodirhodium(II) in L1210 tumor suspension culture.
    Howard RA, Kimball AP, Bear JL.
    Cancer Res; 1979 Jul 15; 39(7 Pt 1):2568-73. PubMed ID: 445459
    [Abstract] [Full Text] [Related]

  • 19. Effect of triamterene on nucleic acid synthesis.
    Chang JC, Hall TC.
    Clin Pharmacol Ther; 1972 Jul 15; 13(3):372-6. PubMed ID: 5026377
    [No Abstract] [Full Text] [Related]

  • 20. Effects of benzohydroxamic acids on L1210 lymphoid leukemia cell nucleic acid metabolism.
    Hall IH, Taylor K, Izydore RA, Daniels DL.
    Pharmazie; 1998 Nov 15; 53(11):794-9. PubMed ID: 9853360
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.